Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03269136 · ClinicalTrials.gov registry record · Phase 1
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 101
- Enrollment target
NCT03269136 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 101 participants.
The verdict
NCT03269136, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 101 participants
- Enrollment target
Study Summary
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Interventions
- DRUG PF-06863135 monotherapy IV or SC
- DRUG PF-06863135 + dexamethasone
- DRUG PF-06863135 + lenalidomide
- DRUG PF-06863135 + pomalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2017-11-29 |
| Est. Completion | 2024-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03269136
The ClinicalTrials.gov registry entry for NCT03269136 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which PF-06863135 monotherapy IV or SC is the first listed.
NCT03269136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03269136 about?
NCT03269136 is a clinical study titled "PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma". To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
What is the current status of trial NCT03269136?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2017-11-29. Estimated completion is 2024-01-19.
What interventions are being tested in trial NCT03269136?
The interventions under investigation include: PF-06863135 monotherapy IV or SC (DRUG), PF-06863135 + dexamethasone (DRUG), PF-06863135 + lenalidomide (DRUG), PF-06863135 + pomalidomide (DRUG).
Who is sponsoring clinical trial NCT03269136?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.